NCT07837063Not yet recruiting
Monitoring Treatment Response With Urine and Serum Metabolome Markers in Patients Treated With Novel Hormone Therapy and Have Either Hormone Sensitive Metastatic Prostate Cancer or Disease Progression on Treatment.
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
80% of patients with newly diagnosed metastatic hormone sensitive prostate cancer have bone metastases. There are mutations that are described with early disease progression when on hormone therapy for prostate cancer. In the NHS setting it is difficult to detect and monitor the patients. There are biochemical changes in the body that are associated with bone metastasis which can be detected in bodily fluids such as urine. Metabolites are substances involved in metabolism (= the chemical processes in the body needed for life. They are usually small molecules. Metabolomics is a way of studying the 'metabolome' which is the entire complement of small molecules present within the body. The metabolites are very sensitve to environmental or other changes and these can be markers for change caused by prostate cancer metastasis. Therefore the urinary metabolome is is potentially a very good indicator of change caused by cancer and hormone treatment. Accurate and specific urine tests would be a way to allow better monitoring of patients. This study aims to investigate the changes of specific bone urinary metabolome markers (UMMs) and untargeted urine profiles to detect the response and progression of patients with prostate cancer (PC). We propose that UMMs are simpler, less difficult for patients and more sensitive and specific compared to conventional imaging and routine blood tests, the current gold standard.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 40 (estimated)
- First submitted
- 7 Sept 2026
- Start date
- Sept 2026
- Primary completion date
- 3 Sept 2029
- Lead sponsor
- The Clatterbridge Cancer Centre NHS Foundation Trust
- Diseases
- Prostate cancer
- NCT number
- NCT07837063
What you commit to
- Study type: Observational
- Planned participants: 40
- From Sept 2026 to the primary completion date, 3 Sept 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \- Non-metastatic prostate cancer (i.e. patients with only prostate and regional lymph node involvement are not eligible).
Other
- Patients who have been \>3 months on ADT (aLHRH (any type) or LHRH (any type) ) at screening are not eligible
- Group 1-3 already commenced abiraterone, apalutamide, darolutamide or enzalutamide
- Group 1-3 already commenced docetaxel for mHSPC
Who the study is looking for
- \- Male 18 years of age or older
- Diagnosis of metastatic adenocarcinoma of the prostate (either histologically confirmed or PSA \>100 and multiple bone metastasis and or abnormal MRI prostate compatible with metastatic prostate cancer)
- Previous radical prostatectomy or radical radiotherapy is allowed
- Bisphosphonate therapy (any type) is allowed but needs to be continued throughout the time on study
- Bicalutamide, aLHRH (any type) or LHRH (any type) should be continued throughout the study period.
- Any medication to treat medical conditions (for example hypertension) at enrolment are allowed and should be continued. These should be recorded on the CRF.
- If the patient takes any complementary therapies (for example cannabis oil), potential risks and drug interactions should be discussed with the patient. If the patient decides to continue with the medication, they should be recorded on the CRF.
- Group 1-3:
- Metastatic (M1) hormone sensitive prostate cancer (conventional or PSMA PET or MRI imaging).
- Any pelvic lymph nodes (N0 - N1) and any local disease stage (T1-T4)
- Group 1:
- Visceral (M1b) or lymph node (M1a) metastasis, up to 5 bone metastasis
- Treatment decision for darolutamide by clinician Group 2
- High volume bone metastasis (\>5), other sites are allowed (M1a or 1b)
- Treatment decision for darolutamide by clinician Group 3
- Any metastasis, M1a or 1b)
- Treatment decision for darolutamide and docetaxel by clinician
- Group 4
- Metastatic disease progression on PSA, imaging, or both.
- Currently on abiraterone, apalutamide, darolutamide or enzalutamide
- PSA progression is defined as 3 consecutive raises above nadir and \> 2ng/ml over a period of 3 months, PSA doubling time \<12 months
- Imaging can be any of the following: CT scan, NM bone scan, PSMA PET, MRI.
- Prior chemotherapy for mHSPC or CRPC is acceptable, but not mandatory
- Any treatment decision by clinician according to patient fitness, wishes and previous treatment according to standard of care protocols for CRCP is allowed.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Clatterbridge Cancer Centre NHS Foundation Trust Coordinator of this site? Confirm its status | Liverpool | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.